Dupilumab-induced Eosinophilic Granulomatosis with Polyangiitis Complicated by Peripheral Neuropathic Pain: a Case Report and Literature Review

作者：Jiajun Wu, Linlin Li, Weidong Ten, Yuchen Wang, Ruiqi Liu, Binbin Hu, Jun Tan, Feilin Dong, Kaiwen Shi, Haibo Zhang, Lizhong Su, Weiming Hu · 发表于：Journal of Clinical Immunology · 年份：2025 · DOI：10.1007/s10875-025-01914-x · 被引用次数：8 · 研究领域：Vasculitis and related conditions、Eosinophilic Disorders and Syndromes、Sinusitis and nasal conditions

PURPOSE: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare vasculitis characterized by increased eosinophils in human tissues and peripheral blood. In this case, we present a 53-year-old female patient with EGPA. By this case and literature review, we want to explain the early manifestations, diagnosis, and management of EGPA, which will help clinicians to understand the disease and attach importance to the possibility of dupilumab-induced EGPA, to improve the early diagnosis rate of EGPA, and reduce misdiagnosis and missed diagnosis. METHODS: The diagnostic criteria for EGPA established by the American Rheumatology Association (ACR) in 2022 were used; these criteria encompass clinical presentation, laboratory tests, and pathological biopsy. In addition, we conducted a comprehensive literature review on this case. RESULT: We present a 53-year-old female patient who developed severe peripheral neuropathic pain after the administration of dupilumab for the treatment of refractory asthma and sinusitis. The patient's symptoms, laboratory examination findings, and nasopharyngeal biopsy pathology results collectively support the diagnosis of EGPA. When dupilumab was converted to mepolizumab combined with glucocorticoid, her peripheral neuropathic pain and asthma symptoms were dramatically relieved. Our literature review also provides a detailed discussion on the relationship between Dupilumab and EGPA. CONCLUSION: We present a case of EGPA with peripheral neuropathic p...